Results 21 to 30 of about 14,398,598 (290)
, 2022 Immunotherapy with bispecific T cell engagers has shown efficacy in patients with hematologic malignancies and uveal melanoma. Antitumor effects of bispecific T cell engagers in most solid tumors are limited due to their short serum half-life and ...
Victor Arias +32 more
core +1 more source
Clinical Case Reports, 2020 The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.
Francesco Paolo Tambaro +8 more
doaj +1 more source
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies [PDF]
, 2020 The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma.
Locatelli F.
core +2 more sources
Bi-, tri-, and multi-specific T-cell engager therapies in glioblastoma: a decade of preclinical innovation [PDF]
Exploration of NeuroscienceBackground: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, with a poor prognosis despite advances in treatment options. T-cell-engager therapies, which have an antibody-based structure connecting immune cells to
Adam H. Lapidus, Malaka Ameratunga
doaj +1 more source
Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? [PDF]
Clinical and Experimental Immunology, 2023 Summary B and T cells collaborate to drive autoimmune disease (AID). Historically, B- and T-cell (B–T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B-cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis ...
Kavina Shah +6 more
openaire +3 more sources
Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy
Haematologica, 2023 T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that a complex interplay between immune cells and tumor cells is implicated in the mechanism of action and therefore,
Casey, M +7 more
openaire +6 more sources
Bispecific T‐cell engagers for cancer immunotherapy [PDF]
Immunology & Cell Biology, 2014 Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single‐chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T‐
Amelia M, Huehls +2 more
openaire +2 more sources
Generalizable design parameters for soluble T cell receptor-based T cell engagers [PDF]
Journal for ImmunoTherapy of Cancer, 2022 While most biological and cellular immunotherapies recognize extracellular targets, T cell receptor (TCR) therapeutics are unique in their ability to recognize the much larger pool of intracellular antigens found on virus-infected or cancerous cells.
Karen J Froning +3 more
openaire +3 more sources
T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies. [PDF]
, 2022 Chimeric antigen receptor (CAR) T-cell and bispecific T-cell engager (BiTE) therapies have revolutionized the treatment of refractory or relapsed leukemia and lymphoma.
Ganatra, Sarju +2 more
core +1 more source
The landscape of bispecific T cell engager in cancer treatment
Biomarker Research, 2021 T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies
Shujie Zhou +4 more
doaj +1 more source